HLA Class 1 vs 2: What Are the Key Differences?

HLA class I and class II molecules are both part of the same immune surveillance system, but they do fundamentally different jobs. Class I molecules sit on the surface of nearly every nucleated cell in your body and display fragments of whatever proteins the cell is making internally, while class II molecules appear mainly on specialized immune cells and display fragments of material the cell has picked up from outside. That division of labor determines which branch of the immune system responds and to what kinds of threats. The differences between the two classes run deep, from molecular architecture and gene location to the diseases they influence and even how they affect organ transplant survival.

How the Two Classes Are Built

Class I and class II molecules are both anchored in the cell membrane, but they are assembled from different pieces. A class I molecule consists of one large protein chain (the heavy chain, encoded by HLA-A, HLA-B, or HLA-C genes) paired with a smaller, invariant partner called β2-microglobulin. The heavy chain does most of the work: its outermost two domains fold together to form the groove where a peptide fragment sits for display. β2-microglobulin stabilizes the whole structure but does not contact the peptide directly.

A class II molecule, by contrast, is made of two similarly sized chains, an α chain and a β chain, both encoded within the HLA region. Each chain contributes one domain to the peptide-binding groove, so the groove is a true partnership between the two chains. This structural arrangement has consequences for what each class can hold. The class I groove is essentially closed at both ends: conserved amino acids form walls that pin the peptide’s two tips in place, limiting the peptide to roughly eight to ten amino acids in length. In the class II groove, smaller amino acids replace those bulky wall residues, lowering the barriers at both ends and allowing longer peptides to thread through and hang over the edges.¹ Class II-bound peptides typically run thirteen to twenty-five amino acids long, though only a core stretch of about nine residues actually contacts the groove floor.

Where Each Class Shows Up on Your Cells

Class I molecules are expressed on virtually every nucleated cell in the body. Red blood cells, which lack a nucleus, are the main exception. This broad expression makes sense given class I’s role: it lets the immune system check almost any cell for signs of viral infection or abnormal protein production. If a virus hijacks a liver cell, that cell’s class I molecules will display viral peptides on the surface, flagging it for destruction.

Class II molecules have a much more restricted distribution. Under normal conditions they appear mainly on professional antigen-presenting cells: dendritic cells, macrophages, and B cells. These are the cells whose job is to patrol the body, engulf debris and pathogens, and alert the rest of the immune system. Certain other cell types, like thymic epithelial cells, also express class II constitutionally, but for most tissues, class II expression is either absent or induced only under inflammatory conditions. Interferons play a major role in that induction, as discussed further below.

Different Sources of Antigen

The two classes sample from different pools of protein. Class I molecules present peptides derived from proteins made inside the cell, sometimes called the endogenous pathway. A cell’s own proteins are continuously broken down by a protein-shredding machine called the proteasome, and the resulting fragments are shuttled into the endoplasmic reticulum, loaded onto class I molecules, and sent to the cell surface. This is how the immune system monitors what a cell is producing internally. If a virus or intracellular bacterium forces the cell to make foreign proteins, fragments of those proteins end up displayed on class I.²

Class II molecules, on the other hand, present peptides from the extracellular environment, sometimes called the exogenous pathway. Antigen-presenting cells engulf bacteria, toxins, or cellular debris from their surroundings, break these materials down in acidic compartments called endosomes and lysosomes, and load the resulting peptides onto class II molecules for surface display.² This is how the immune system learns about threats circulating in the blood or lurking in tissues without needing those threats to actually infect a cell first.

There is an important exception to this tidy separation. Dendritic cells and some macrophages can take material from outside the cell and load it onto class I molecules, a trick called cross-presentation.³ Cross-presentation is critical for launching immune responses against tumors and viruses that do not directly infect dendritic cells. Without it, the immune system would struggle to activate the killer T cells needed to eliminate those threats.⁴

Which T Cells Respond

The class distinction maps directly onto the two major arms of T cell immunity. Class I molecules are recognized by CD8-positive T cells, also known as cytotoxic or killer T cells. When a CD8 T cell’s receptor locks onto a class I molecule displaying a suspicious peptide, the T cell can kill the presenting cell outright. Class II molecules are recognized by CD4-positive T cells, often called helper T cells. When a CD4 T cell engages a class II molecule on an antigen-presenting cell, it responds by releasing chemical signals that coordinate a broader immune response, helping B cells make antibodies and ramping up other immune defenses.⁵

The CD4 and CD8 proteins themselves function as co-receptors, physically binding to the class II and class I molecules respectively. This binding stabilizes the interaction and helps ensure that CD4 T cells respond only to class II-presented antigens, while CD8 T cells respond only to class I-presented antigens. The system is not perfectly airtight, but the co-receptor pairing enforces a strong division of labor that shapes the entire downstream immune response.

The Peptide Loading Machinery

Each class relies on its own set of helper molecules to load peptides correctly. For class I, the key players include the TAP transporter, which pumps peptide fragments from the cytoplasm into the endoplasmic reticulum, and tapasin, which acts as both a chaperone and a quality-control editor. Tapasin holds the class I molecule in a peptide-receptive state and helps swap out weakly binding peptides for ones that fit more snugly, ensuring that the molecule reaches the cell surface loaded with a stable cargo.⁶

For class II, the equivalent editor is HLA-DM. Newly made class II molecules travel through the cell with a placeholder peptide (called CLIP) sitting in their groove. HLA-DM catalyzes the removal of CLIP and promotes loading of peptides that have been generated in the endosomal compartments. A second accessory molecule, HLA-DO, modulates HLA-DM’s activity and is mainly active in B cells, where it may bias peptide selection in ways that favor high-quality antibody responses.⁶ Despite performing analogous roles, tapasin and HLA-DM are structurally unrelated proteins that evolved to solve the same problem in different cellular compartments.

Genetic Organization

All HLA genes sit on the short arm of chromosome 6, within a stretch of DNA known as the major histocompatibility complex.⁷ The classical class I genes, HLA-A, HLA-B, and HLA-C, cluster toward one end of the region. The classical class II genes, HLA-DR, HLA-DQ, and HLA-DP, occupy the other end. Sandwiched between them is the class III region, which despite its name does not encode antigen-presenting molecules at all. Class III genes handle a grab-bag of immune functions including complement proteins, tumor necrosis factor, and heat-shock proteins.⁸

Both class I and class II genes are among the most polymorphic in the human genome, meaning they exist in thousands of variant forms across the population. This diversity is maintained by natural selection: a population with many different HLA variants is better equipped to handle a wide range of pathogens, because different variants bind different peptide fragments. The practical consequence is that finding an HLA-matched organ donor can be extremely difficult, because the odds of two unrelated people sharing the same set of variants at multiple loci are low.

How Interferons Shift the Balance

Both class I and class II expression can be ramped up by interferons, the signaling molecules your body releases during infection, but the two classes respond differently. In one study of human blood cells, interferon-alpha and interferon-gamma each boosted class I expression by roughly one-and-a-half to twofold on both lymphocytes and monocytes. Class II expression, however, showed a sharper divide: lymphocytes did not express detectable class II even after interferon stimulation, while monocytes, which already had high baseline class II levels, saw further increases of up to twofold with interferon-alpha and up to fivefold with interferon-gamma.⁹

This asymmetry matters during infections. A viral assault triggers interferon release, which cranks up class I on infected cells so that killer T cells can find them more easily. The same interferons also boost class II on the professional antigen-presenting cells that coordinate the broader immune response. But the system keeps class II off most other cell types even during inflammation, preventing inappropriate activation of helper T cells against normal tissue. In some disease states, however, this regulation goes awry, and class II can appear on cells that normally never display it, a phenomenon linked to autoimmune conditions.

Disease Associations

Both classes are tied to autoimmune disease, but the patterns differ. Class II associations have been recognized longer and tend to be among the strongest genetic risk factors known. Specific variants of HLA-DR and HLA-DQ are linked to rheumatoid arthritis, type 1 diabetes, and Graves’ disease. More recently, researchers have identified independent class I contributions: HLA-B variants are associated with type 1 diabetes risk, and HLA-C variants with multiple sclerosis and Graves’ disease.¹⁰ The fact that both classes contribute, sometimes to the same disease through independent genetic effects, underscores how tightly the entire HLA system is woven into immune regulation.

In organ transplantation, the two classes exert their influence on different timescales. During the first year after a transplant, mismatches at the class II HLA-DR locus have a stronger impact on graft survival than mismatches at class I loci HLA-A and HLA-B. In subsequent years, however, the influence of all three loci becomes equivalent and additive, meaning long-term survival benefits from matching at every available locus.¹¹ The early dominance of class II matching likely reflects the central role of CD4 helper T cells in initiating rejection responses.

Cancer and Immune Evasion

Tumor cells face a dilemma: they need to stay alive, but their class I molecules are broadcasting abnormal peptides that could attract killer T cells. One common escape strategy is to lose class I expression altogether. In a study of cancer patients receiving immune checkpoint therapy, about a quarter showed loss of heterozygosity at class I HLA loci, meaning tumor cells had deleted one copy of their class I genes. Patients with this loss had significantly shorter survival, with a median overall survival of 8 months compared with about 11 months for patients whose tumors retained intact class I. The worst-off group, with both low tumor mutation burden and class I loss, had a median survival of only about 5 months.¹²

Losing class I helps tumors hide from CD8 killer T cells, but it creates a different vulnerability. Natural killer cells are trained to attack cells that lack normal class I expression, operating on a “missing self” principle. Tumors that downregulate class I to dodge T cells may instead attract NK cell attention. This tug-of-war between immune evasion strategies is one reason cancer immunology is so complicated, and why therapies targeting only one arm of the immune system sometimes fall short.

Drug Hypersensitivity Reactions

Some of the most clinically actionable HLA findings involve drug reactions, and class I has been the main player here. Over the past two decades, specific class I alleles have been strongly linked to severe T cell-mediated drug hypersensitivity. The best-known example is HLA-B*57:01 and the HIV drug abacavir. Screening patients for this allele before prescribing abacavir has a near-perfect ability to identify who will not react, and this pre-prescription genetic test has been adopted worldwide.¹³ The prevalence of HLA-B*57:01 varies by population, ranging from about 1% to 3% in the Greater Middle East, for instance.¹⁴

Class II alleles are also implicated in some drug reactions. HLA-DPB1*03:01, for example, has been associated with aspirin-induced asthma, with allele prevalence ranging from about 10% to 14% in Middle Eastern populations.¹⁴ But the picture is incomplete: for most drugs that cause hypersensitivity, the responsible HLA allele has not been identified, and an allele linked to risk in one ethnic group does not necessarily predict risk in another. Even when a risk allele is known, carrying it is necessary but not sufficient for a reaction, so the positive predictive value of testing tends to be low.¹³ Abacavir remains the success story; for other drugs, pharmacogenomic testing is still a work in progress.

Non-Classical Class I Molecules and Pregnancy

Beyond the classical HLA-A, -B, and -C genes, several non-classical class I genes encode molecules with specialized roles. The most striking is HLA-G, which is expressed almost exclusively on cells at the boundary between a mother and her developing fetus. The fetus is genetically half foreign, carrying paternal HLA variants the mother’s immune system has never seen. HLA-G interacts with receptors on maternal immune cells, including NK cells, T cells, macrophages, and dendritic cells, dampening their activity and helping maintain immune tolerance at the maternal-fetal interface.¹⁵ Reduced HLA-G expression has been associated with complications like recurrent miscarriage and preeclampsia, reinforcing the idea that this molecule is a pivotal protective factor in pregnancy.

Evolutionary Origins

One of the more surprising recent discoveries in this field concerns which class came first. For years, the evolutionary relationship between class I and class II was unclear. Then researchers identified an ancient category of MHC molecules, dubbed the W-category, in cartilaginous fish such as sharks. W-category molecules have the two-chain organization typical of class II but carry sequence motifs specific to class I, including a domain that resembles β2-microglobulin. This mosaic structure suggests that class I molecules evolved from a class II-like ancestor, meaning class II is the older form.¹⁶

Genomic analysis of shark MHC regions supports this picture. Class I, class II, β2-microglobulin, and antigen-processing genes all cluster together in what appears to be an ancestral “adaptive MHC” core region, suggesting these components were already organized as a functional unit early in the evolution of jawed vertebrates. The current model places the emergence of this core after a major genome duplication event that occurred hundreds of millions of years ago.¹⁷ The human HLA system, with its elaborate separation of class I and class II regions, is a much later refinement of that ancient arrangement.

1
Structure. Antigenic peptide binding by class I and class II histocompatibility proteins
2
PubMed. The HLA system, antigen processing and presentation
3
PubMed Central. Cross-presentation of exogenous antigens on MHC I molecules
4
Annual Reviews. The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules
5
Nature. Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen
6
PubMed. HLA-DM, HLA-DO and tapasin: functional similarities and differences
7
PubMed Central. The HLA system: genetics, immunology, clinical testing, and clinical implications
8
Nature. Human leukocyte antigen super-locus: nexus of genomic supergenes, SNPs, indels, transcripts, and haplotypes
9
PubMed Central. Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells
10
PubMed Central. The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
11
PubMed. HLA compatibility and organ transplant survival. Collaborative Transplant Study
12
Cancer Discovery. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response
13
PubMed Central. Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions
14
PubMed. HLA pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the Greater Middle East
15
PubMed Central. HLA-G: An Important Mediator of Maternal-Fetal Immune-Tolerance
16
PubMed Central. Discovery of an ancient MHC category with both class I and class II features
17
Molecular Biology and Evolution. An Ancestral Major Histocompatibility Complex Organization in Cartilaginous Fish: Reconstructing MHC Origin and Evolution